(December 7, 2016, 1:30 PM EST) -- BOSTON — A First Circuit U.S. Court of Appeals panel on Nov. 28 substantially affirmed a federal district court’s dismissal of claims in a securities class action lawsuit against a pharmaceutical company, certain of its current and former officers and directors and others, ruling that shareholders failed to plead a material misrepresentation or scienter in arguing that the defendants violated federal securities laws by misrepresenting clinical trial results for the company’s cancer drug (In re ARIAD Pharmaceuticals Inc. Securities Litigation, No. 15-1491, 1st Cir.)....